Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (2007)
16 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2007
Slide 1: Fisher & Paykel Healthcare
HEALT HG ARE Fisher &Paykel
Slide 2: Consistent Growth Strategy
Consistent Growth Strategy • Innovative devices which improve care and outcomes • Increase value per patient • New patient groups • International expansion 1
Slide 3: Financial Highlights
Financial Highlights • Trading revenue NZ$349M +21% • Operating profit NZ$90M -14% • Operating margin 25.7% • R&D investment at 5.8% of revenue 2
Slide 4: Sales by Product Group
Sales by Product Group Distributed/ Neonatal Other 8% 3% OSA 46% Respiratory Humidification 43% Trading revenue 12 months to 31 March 2007 3
Slide 5: Sales by Region
Sales by Region Asia Pacific/ Other 20% North America 49% Europe 31% Trading revenue 12 months to 31 March 2007 4
Slide 6: Expanding International Presence
Expanding International Presence 5
Slide 7: Obstructive Sleep Apnea
Obstructive Sleep Apnea 6
Slide 8: Obstructive Sleep Apnea
Obstructive Sleep Apnea • OSA treatment market growing rapidly • 27% revenue growth to NZ$162M • 34% combined mask and flow generator revenue growth 7
Slide 9: Flow Generators & Masks
Flow Generators & Masks • Introduced FlexiFit™ Full Face Mask • Introduced Opus™ Nasal Pillows Mask • ThermoSmart™ proportion growing 8
Slide 10: Respiratory Humidification
Respiratory Humidification 98
Slide 11: Respiratory Humidification
Respiratory Humidification • 15% revenue growth to NZ$150M • Humidifier controller placement driving breathing circuit market share • Good early acceptance of new respiratory interfaces, NIV, 02 therapy, humidity therapy 10
Slide 12: Neonatal
Neonatal • 25% revenue growth to NZ$27M • Very strong growth for Bubble CPAP, Neopuff resuscitator • Good early demand for new O2 therapy system, resuscitation masks 11
Slide 13: Research & Development
Research & Development • New product pipeline – Masks – Flow Generators – Humidity therapy system – Consumables 12
Slide 14: Planning for growth
Planning for growth 13
Slide 15: First Half Outlook
First Half Outlook • Operating revenue – US$125M – US$130M approx. – NZ$170M – NZ$175M approx. • Operating profit – NZ$32M approx. 14
Slide 16: Fisher & Paykel Healthcare
HEALT HG ARE Fisher &Paykel
Fisher & Paykel Healthcare — Shareholder Meeting (2007) on 6ix